RxDoctor Payments Data

Mikaella Garcia

Psychiatric/Mental Health · Rio Rancho, NMNPI 1477338341

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.4% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations.

$1,685in general payments, 2019–2025

Across 40 payments — averaging $42.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$304
  • Otsuka America Pharmaceutical, Inc.$288
  • Neuronetics, Inc.$254
  • Teva Pharmaceuticals USA, Inc.$247
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$141
  • Neurocrine Biosciences, Inc.$139
  • plus $312 from 7 others

What the payments were for

  • Food & beverage$1,57393%
  • Education$1117%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,685 in reported general payments places this provider in the 80th percentile of 228 psychiatric/mental health providers in New Mexico.

See all psychiatric/mental health providers in New Mexico

Medicare billing

Part B allowed, 2024
$24,167
Medicare patients
32
Services billed
207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl14$29,079
Aripiprazole36$4,823
Olanzapine47$1,877
Prazosin Hcl48$1,756
Quetiapine Fumarate91$1,417
Risperidone45$968
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine16$927
Lamotrigine66$669
Trazodone Hcl49$626
Duloxetine Hcl36$566
Bupropion XlBupropion Hcl24$557
Sertraline Hcl65$500
Buspirone Hcl25$487
Propranolol Hcl31$471
Venlafaxine Hcl ErVenlafaxine Hcl23$361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$304$29,07914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 228 psychiatric/mental health providers in New Mexico.

Other psychiatric/mental health in Rio Rancho

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →